2. Academic Validation
  3. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin

LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin

  • Bioanalysis. 2016 Feb;8(3):193-204. doi: 10.4155/bio.15.238.
Yongxin Zhu 1,  Celia D'Arienzo 1,  Zhen Lou 1,  Alexander Kozhich 1,  Malavi Madireddi 1,  Anjaneya Chimalakonda 1,  Adrienne Tymiak 1,  Timothy V Olah 1
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543, USA.
PMID: 26811930 DOI: 10.4155/bio.15.238
Abstract

Background: Therapeutic protein discovery study highlights the need for the development of quantitative bioanalytical methods for determining the levels of both the therapeutic protein and the target protein, as well.

Results: For the quantitation of BMS-986089, both accuracy (99-103%) and precision (2.4-12%) were obtained for the analysis of the surrogate peptide (ITYGGNSPVQEFTVPGR), in addition to the accuracy (100-108%) and precision (0.7-18%) that were obtained for the analysis of the surrogate peptide (VVSVLTVLHQDWLNGK). For Myostatin, accuracy (94-103%) and precision (2.4-14.9%) were obtained for the analysis of the surrogate peptide (IPAMVVDR).

Conclusion: The developed method was applied to the analysis of samples following dosing of BMS-986089 to mice. This method highlights the potential of LC-MS/MS-based methods to eventually assess in vivo drug-target engagement.

Keywords

LC–MS/MS-based multiplexed detection; surrogate peptides; target protein; therapeutic protein.

Figures
Products